Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
NCT ID: NCT06203249
Last Updated: 2024-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50 participants
OBSERVATIONAL
2024-01-20
2026-11-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on Lymphocyte Subsets of Peripheral Blood in Patients With Nonmyopathic Dermatomyositis Complicated With Pulmonary Interstitial Disease
NCT06149039
Intestinal Flora and Immunity in Monoclonal Gammopathy Patients
NCT06539832
Role of the Host Microbiota and Il-17 in Favoring Multiple Myeloma Progression
NCT05712967
The Role of Inflammasome in Inflammatory Macrophage in Mycobacterium Avium Complex-lung Disease and Mycobacterium Abscessus-lung Disease
NCT02005094
Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
NCT06690593
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD.
* Must have undergone bronchoalveolar lavage.
* Age≥18 years old.
* Patients who signed informed consent forms
Exclusion Criteria
* Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors.
* Pregnant or lactating patients.
* The patient also participated in any other clinical trial.
* Disagreement for inclusion in this study
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese PLA General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
wang kaifei
Chinese PLA General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
PLA
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Microecology and Immunity 1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.